(MENAFNEditorial)
France will remain among the largest pharmaceutical markets worldwide in the coming years especially due to a large and aging population as well as high per capita spending level s on medicines. However several cost-containment measures will continue to exert downward pressure on market growth over a multi-year horizon. On the upside current macroeconomic trends including low oil and food prices should be net positive for household consumption in France posing upside risks to market forecasts in the medium - and long - term .
Headline Expenditure Projections
* Pharmaceuticals: EUR33.06bn (USD44.29bn) in 2014 to EUR32.43bn (USD40.54bn) in 2015; -1.9% in local currency terms and -8.5% in US dollar terms. Forecast in line with last quarter.
* Healthcare: EUR252.14bn (USD337.87bn) in 2014 to EUR259.42bn (USD324.27bn) in 2015; +2.9% in local currency terms and -4.0% in US dollar terms. Forecast in line with last quarter.
Full Report Details at
- http://www.fastmr.com/prod/957412_france_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=101
Risk/Reward Index
In Q215 France maintains an overall Risk/Reward Index (RRI) score of 71.7 out of 100. This means that France stands as the fourth most attractive market to pharmaceutical investors out of 15 markets in Western Europe. France's score is driven by the large multi-billion dollar drug market (market expenditure score of 16.0 out of 20) and large pensionable population (pensionable population score of 8.0 out of 8) but dragged down by poor market expansion (sector value growth score of 0.0 out of 12).
Key Trends And Developments
* In January 2015 Roche agreed to acquire Trophos a privately held biotechnology company based in Marseille France. Trophos' proprietary screening platform generated olesoxime (TRO19622) which is being developed for spinal muscular atrophy a rare and debilitating genetic neuromuscular disease commonly diagnosed in children. Under the terms of the agreement Trophos's shareholders will receive an upfront cash payment of EUR120mn plus additional contingent payments of up to...
The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's France Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for France to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
* Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in France.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.